SENP1 drives glycolysis and cisplatin resistance in gastric cancer via desumoylating ENO1
SENP1 facilitates gastric cancer progression by metabolic reprogramming. Targeting SENP1 with Momordin Ic is a novel therapeutic approach for GC patients.
Authors
- Pei Ma (ORCID: https://orcid.org/0000-0002-3388-1022)
- Yangyue Xu
- Xi Wu (ORCID: https://orcid.org/0009-0002-5996-4624)
- Yunru Gu (ORCID: https://orcid.org/0000-0001-5860-5588)
- Yuan Fang (ORCID: https://orcid.org/0000-0003-0483-2237)
- Yongqian Shu (ORCID: https://orcid.org/0000-0002-3034-685X)
- Lei Cao (ORCID: https://orcid.org/0000-0002-1157-0303)
- Hao Wu (ORCID: https://orcid.org/0000-0001-8599-3950)
- Xiao Li (ORCID: https://orcid.org/0000-0002-8889-9609)
- Tingting Xu (ORCID: https://orcid.org/0000-0001-5524-035X)
- Zhongliang Xu
- Haoyang Shen
- Peng Wang (ORCID: https://orcid.org/0000-0002-5716-9937)
Institutions
- Jiangsu University (CN)
- Nanjing Drum Tower Hospital (CN)
- Affiliated Hospital of Jiangsu University (CN)
- Jiangsu Cancer Hospital (CN)
- Jiangsu Province Hospital (CN)
- Wuxi People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-10-08
- DOI
- https://doi.org/10.1186/s13046-025-03543-z
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Nanjing Medical University